Streetbeat News

Products Services

VLCN

Volcon, Inc. (NASDAQ:VLCN) shares surged 36.36% to $1.65 after announcing the delivery of its first production vehicle, the Volcon Stag, to the U.S. Army Corps of Engineers for evaluation. This marks a significant rebound following a 100% dip over the last year. The company's CEO, John Kim, highlighted the successful launch of the Stag, the fastest-production electric UTV, and the ongoing full production of Grunt EVO motorcycles. Volcon aims to ramp up Stag production and sales while continuing its electric motorcycle deliveries globally.

Portfolio Pulse from Nabaparna Bhattacharya

February 29, 2024 | 5:37 pm

LUNR

SIDU

Sidus Space, Inc. (NASDAQ:SIDU) shares surged after announcing its LizzieSat satellite is ready for launch with SpaceX, aiming for a March 2024 launch. The satellite will support various industries with its data collection capabilities and onboard AI. The stock's movement is compared to Intuitive Machines, Inc. (NASDAQ:LUNR), which also saw a significant price increase following a successful launch.

Portfolio Pulse from Erica Kollmann

February 29, 2024 | 5:23 pm

BYND

Financial analysis reveals a bullish trend in Beyond Meat's (NASDAQ:BYND) options activity, with 60% of traders showing bullish sentiment. The analysis highlighted 10 unusual trades, with a focus on a price band between $7.0 and $40.0. Beyond Meat, known for its plant-based meats, has seen its stock price decrease by -3.36%, currently trading at $9.5. The company's international revenue accounted for 31% of 2021 sales, with expectations of food-service sales recovering to 50% due to new deals with McDonald's and Yum Brands.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

MRNA

Significant investors have taken a predominantly bearish stance on Moderna (NASDAQ:MRNA), with options data revealing 75% bearish sentiment. The targeted price range for MRNA is between $60.0 and $100.0. Despite this, the current price of MRNA is $93.85, down 3.73%, with neutral RSI indicators. Analysts have mixed opinions, with a consensus target price of approximately $100.67, varying ratings from 'Outperform' to 'Reduce'. Moderna's mRNA technology has seen rapid validation, especially with its COVID-19 vaccine, and it continues to explore various therapeutic areas.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

IOVA

Iovance Biotherapeutics (NASDAQ:IOVA) has seen a surge in options activity, with a notable split between bullish and bearish sentiments among high-rolling investors. The options trades, predominantly calls, target a price range of $7.5 to $30.0. Despite a current price drop of -3.61% to $16.8, professional analysts maintain positive ratings, with a consensus target price of $24.4. The company, a pioneer in T-cell therapy for solid tumor cancers, is preparing for potential U.S. regulatory approval and commercialization.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:01 pm

DNLI

Goldman Sachs has reaffirmed its Buy rating on Denali Therapeutics (NASDAQ:DNLI) but reduced its price target from $73.00 to $50.00. Despite this adjustment, DNLI's shares have risen by 2.62% in the last 24 hours to $20.74. A move to the new target price would represent a 141.08% increase from the current level. Denali Therapeutics is focused on developing treatments for neurodegenerative diseases, with several key products in its pipeline.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 5:00 pm

AMZN

CRM

Salesforce Inc (CRM) exceeded fiscal Q4 estimates with an 11% YoY revenue increase to $9.29 billion but provided weak fiscal 2025 revenue guidance. The company announced a strategic partnership with Amazon.com Inc (AMZN), selling its products on Amazon's cloud marketplace, which is expected to enhance its AI and cloud capabilities. Despite a cautious revenue outlook due to foreign-exchange pressure and a weak professional services sector, Salesforce is optimistic about AI's future contributions to its financials, highlighted by the introduction of Einstein Copilot.

Portfolio Pulse from Upwallstreet

February 29, 2024 | 4:57 pm

TIVC

Tivic Health Systems has filed a patent application (#20240066294) for a microcurrent TMJ treatment device with an adaptive trigger, indicating innovation in medical device technology.

Portfolio Pulse from Charles Gross

February 29, 2024 | 4:56 pm

TIVC

Tivic Health Systems has filed a US patent application (#20240066295) for a microcurrent migraine treatment device featuring an adaptive trigger. This innovation could potentially enhance Tivic Health's product lineup, offering a new solution for migraine sufferers.

Portfolio Pulse from Charles Gross

February 29, 2024 | 4:52 pm

OPRA

Opera Limited (NASDAQ:OPRA) reported a 17% year-on-year increase in Q4 fiscal 2023 revenue to $113.00 million, surpassing the consensus of $112.2 million. EPS per ADS was $1.38, beating the consensus of $0.23, leading to a stock price gain. Monthly active users reached 313 million, with the Opera GX browser user base at 27.8 million, up 7% Q/Q. Search revenue grew by 15% Y/Y to $44.7 million, and advertising revenue increased by 20% Y/Y to $67.8 million. Operating expenses rose by 10% Y/Y, but the adjusted EBITDA margin improved by 90 bps to 24.6%. Opera held $93.9 million in cash and equivalents and generated $25.3 million in operating cash flow. The company expects fiscal 2024 revenue of $450 million to $465 million. OPRA shares were up 2.04% at $11.86.

Portfolio Pulse from Anusuya Lahiri

February 29, 2024 | 4:43 pm